Background: Vitamin D acts as a neuroprotector and modulator in the central nervous system. Hypovitaminosis is a risk factor for cognitive dysfunction. Hypovitaminosis D and impaired cognitive function are common in patients with chronic kidney disease. Impaired cognitive function is comorbid that can increase the morbidity and mortality of patients with chronic kidney disease. This study aims to assess the relationship between serum vitamin D levels and cognitive function in patients with chronic kidney disease. Methods: This research is an observational study with a cross-sectional approach. A total of 60 research subjects participated in this study. Sociodemographic data, cognitive function, and vitamin D levels were analyzed in this study. Data analysis was performed with SPSS 25 to perform univariate and bivariate tests. Results: The impaired cognitive function was found in 56.7% of CKD patients. The median serum vitamin D level of patients with chronic kidney disease with impaired cognitive function was 30.80 ng/mL and without impaired cognitive function 42.98 ng/mL. There was a significant relationship between serum vitamin D levels and impaired cognitive function (OR=4.125, p=0.035). The cut-off point of serum vitamin D levels associated with impaired cognitive function in CKD patients was 34.8 ng/mL (sensitivity 64.7% and specificity 69.2%). Conclusion:There is a significant relationship between serum vitamin D levels and the incidence of cognitive dysfunction in patients with chronic kidney disease. The cut-off point for serum vitamin D levels associated with impaired cognitive function in chronic kidney disease is 34.8 ng/mL.
Background: Epilepsy is one of the most common chronic neurological disorders affecting people worldwide. People with epilepsy have higher mortality rate than general population. Medication adherence is predictor for epilepsy outcome. Number of medication is one of contributing factors to therapy adherence. Aims: to determine antiepileptic drug adherence between monotherapy and polytherapy at Neurology Clinic Dr. M. Djamil Hospital. Methods: This study conducted at Neurology Clinic Dr. M. Djamil Hospital from May to June 2019. Medication adherence was assessed by using Morisky Medication Adherence Scale (MMAS) 8. Data was analyzed and level of significance was if p value ≤ 0.05. Result: We recruited 30 participants which consist of 14 (46.7%) female and 16 (53.5%) male. Median of age 31 (13-77) and 22 (73.3%) patients have high educational level. From 30 patient, 14 (46.7%) in monotherapy and 16 (53.3%) in polytherapy. Patient with high medication adherence 4 (13.3%), moderate 7 (23.3%) and poor 17 (56.7%). Statistical analysis showed no differences on medication adherence between monotherapy and polytherapy (p=0.79). Conclusion: There are no differences on medication adherence between monotherapy and polytherapy at Neurology Clinic Dr. M. Djamil Hospital.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.